Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.

导出 OA

翻译打印收藏纠错

作者： Gerhard,Zugmaier ^[1] ; Nicola,Gökbuget ^[2] ; Matthias,Klinger ^[1] ; Andreas,Viardot ^[3] ; Matthias,Stelljes ^[4] ; Svenja,Neumann ^[5] ; Heinz-A,Horst ^[5] ; Reinhard,Marks ^[6] ; Christoph,Faul ^[7] ; Helmut,Diedrich ^[8] ; Albrecht,Reichle ^[9] ; Monika,Brüggemann ^[5] ; Chris,Holland ^[10] ; Margit,Schmidt ^[1] ; Hermann,Einsele ^[11] ; Ralf C,Bargou ^[12] ; Max S,Topp ^[11]

作者单位： Amgen Research (Munich), Munich, Germany; ^[1] Department of Medicine II, Goethe University Frankfurt, Frankfurt, Germany; ^[2] Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany; ^[3] Department of Medicine A, University of Münster, Münster, Germany; ^[4] Department of Medicine II, Christian-Albrechts-Universität zu Kiel, Kiel, Germany; ^[5] Department of Medicine I, Albert-Ludwigs-Universität Frieburg, Freiburg, Germany; ^[6] Department of Medicine II, Eberhard Karls Universität Tübingen, Tübingen, Germany; ^[7] Department of Hematology and Oncology, Medizinische Hochschule Hannover, Hannover, Germany; ^[8] Department of Medicine III, University of Regensburg, Regensburg, Germany; ^[9] Amgen, Rockville, MD; and. ^[10] Department of Medicine II and. ^[11] Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Würzburg, Germany. ^[12]